ArticleMMWR. Morbidity and mortality weekly report2024
Progress Toward Rubella and Congenital Rubella Syndrome Elimination - Worldwide, 2012-2022.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Rubella and congenital rubella syndrome in the GCC countries: A retrospective ecological analysis of elimination progress and scenario-based projections, 2020-2024.Journal of virus eradication · 2026Article
- Progress Toward Rubella and Congenital Rubella Syndrome Elimination - Worldwide, 2012-2024.MMWR. Morbidity and mortality weekly report · 2026Article
- Notes from the Field: Congenital Rubella Syndrome - Florida, 2025.MMWR. Morbidity and mortality weekly report · 2026Article
- Rubella outbreak investigation in Adigrat town of Eastern Tigray, Northern Ethiopia, 2024: case-control study design.BMC public health · 2026Article
- Progress towards measles and rubella elimination in Eswatini by 2024.PLOS global public health · 2026Article
- Measles and rubella: From global health challenges to advancements in molecular diagnostics in the elimination era.Molecular therapy. Nucleic acids · 2025Review
- Neutrophils at the Maternal-Fetal Interface: Agents of Protection or Destruction?American journal of reproductive immunology (New York, N.Y. : 1989) · 2025Review
- Factors determining the overlap between recipients of the first and second dose of measles vaccine in nineteen surveys.Scientific reports · 2025Article
- Congenital Rubella Syndrome in the Post-Elimination Era: Why Vigilance Remains Essential.Journal of clinical medicine · 2025Review
- Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction - 19 Countries, 2019-2055.MMWR. Morbidity and mortality weekly report · 2025Article
- Epidemiology of Rubella Virus in a Fragile and Conflict-affected Setting - A Retrospective Analysis of 11 Years Case-based Data in South Sudan.Open forum infectious diseases · 2025Article
- Vaccination Status and Incidences of Measles, Mumps, and Rubella - Worldwide, 2014-2023.China CDC weekly · 2025Article
- Ten-year surveillance and epidemiological patterns of measles and rubella: A study in the Babol County.Caspian journal of internal medicine · 2025Article
- The evolving landscape of rubella in the WHO African Region.The Pan African medical journal · 2025Article
- Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.Vaccines · 2024Article
- Article
- Article
- On the Path to Measles and Rubella Elimination Following Rubella-Containing Vaccine Introduction, 2000-2023, Namibia.Vaccines · 2024Article
- The Global Measles and Rubella Laboratory Network Supports High-Quality Surveillance.Vaccines · 2024Article
- Building Quality Control for Molecular Assays in the Global Measles and Rubella Laboratory Network.Vaccines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rubella virus is a leading cause of vaccine-preventable birth defects. Infection during pregnancy can result in miscarriage, fetal death, stillbirth, or a constellation of birth defects, including cataracts, deafness, heart defects, and developmental delay, known as congenital rubella syndrome (CRS). A single dose of rubella-containing vaccine can provide lifelong protection against rubella. The Global Vaccine Action Plan 2011-2020 included a target to achieve elimination of rubella in at least five of the six World Health Organization (WHO) regions by 2020, and rubella elimination is a critical goal of the Immunization Agenda 2030. This report updates a previous report and describes progress toward rubella and CRS elimination during 2012-2022. During 2012-2022, among 194 WHO countries, the number that included rubella-containing vaccine (RCV) in their immunization schedules increased from 132 (68%) to 175 (90%) and the percentage of the world's infants vaccinated against rubella increased from 40% to 68%. Reported rubella cases declined 81%, from 93,816 in 2012 to 17,407 in 2022. Verification of rubella elimination was achieved in 98 (51%) of 194 countries by 2022, an increase from 84 (43%) countries in 2019. Despite significant progress in the introduction of RCV into routine immunization programs worldwide, approximately 25 million infants annually still do not have access to RCV. Nevertheless, even in complex settings, the increasing number of countries that have achieved and sustained rubella elimination demonstrates progress toward global rubella elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.